A password will be e-mailed to you.

New Alzheimer’s Biomarker Identified with Help of CRISPR

Summary: With the aid of CRISPR gene editing techniques, researchers have identified a new biomarker for Alzheimer’s disease. The study reports a deficiency of the protein STIM1 could be implicated in the sporadic version of the neurodegenerative disease.

Source: University of Extremadura.

The objective of the research, undertaken in the laboratories of the IBPM, is to develop a model for studying Alzheimer’s disease (AD) of sporadic origin, in other words, not due to a hereditary genetic mutation. While Alzheimer’s disease of familial or hereditary type is responsible for around 5% of all cases, it is thought that 95% of its incidence is of unknown or sporadic origin.

“In Alzheimer’s of family origin, there already exist animal models, because we know which genes are linked to this illness. However, in Alzheimer’s disease of unknown origin, to date there are no models that enable us to study how it develops”, according to Francisco Javier Martin-Romero, one of the authors of the study.

These researchers analysed cultures of damaged brain tissue from a region called Medial Frontal Gyrus, with clinically confirmed alterations provoked by Alzheimer. These clinical samples were analysed and compared with healthy tissue from patients of the same age. As a result of this comparative study, the scientists found a deficiency in the protein STIM1 in brain tissue from patients with Alzheimer’s disease.

“We have been working with this protein for 10 years, but we weren’t expecting these results with sporadic Alzheimer’s”, adds Martin-Romero. The next step the researchers took was to observe the involvement of this protein STIM1 in the neurodegeneration of the neuron, and they did so using the genetic editing system CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), known as the “genetic cut-and-paste”. The researchers applied a strategy to eliminate the expression of the gene STIM1 in the neuroblastoma SH-SY5Y cell line, editing the genome with CRISPR / Cas9, using an in vitro model to examine the phenotype of the neuronal cells deficient in STIM1.

“We use the CRISPR technique on a regular basis in the Faculty of Sciences at the UEx, as it has the great advantage that the genome remains stable despite the cuts in the DNA. In this specific case, the procedure CRISPR silences the gene which permits the expression of the protein STIM1 in the neuron. Thus, we were able to simulate what occurs in the neuron without this protein, and we observed alterations very similar to those seen in tissues with Alzheimer’s”, the researcher emphasises. Up to now, the effects of a deficiency in this protein critical to sporadic Alzheimer’s were not known, and so this research gives us a new biomarker for the illness, in other words, an indicator of the progression of the neurodegenerative process.

neurons

The scientists have found a deficiency in the protein STIM1 in brain tissue from patients with Alzheimer’s disease. Its involvement in neurodegenerative processes has been verified thanks to the technique CRISPR/Cas9. Up to now, the effects of a deficiency in this protein critical to sporadic Alzheimer’s were not known. NeuroscienceNews.com image is credited to UEx.

One of the alterations observed due to the deficiency of STIM1 is in the transport of calcium ions through the plasma membrane of the neurons. “This calcium is necessary for the cell to be fully viable, and an alteration in this process affects its entire physiology, finally causing its death. The cell is unable to halt the transport of calcium, which becomes unregulated and out of control”, states Martin-Romero. The investigator highlights that this transport takes place through calcium ion channels regulated by a voltage. These voltage-gated calcium channels, the so-called L-type, can be blocked using pharmaceuticals based on dihydropyridine. In fact, the team of researchers was able to halt cell death in vitro using pharmaceuticals based on dihydropyridine because of that blocking action, representing an important new finding in the treatment of Alzheimer’s.

The next step for the investigators at the IBPM will be to work with pluripotent stem cells and differentiate them into neurons, firstly for mice and then for humans, to make development of a model possible. This will allow a description of how the absence of stimulus or reduction in the protein STIM1 determines cell aging in sporadic Alzheimer’s disease.

About this neuroscience research article

Funding: Spanish Ministerio de Economia y Competitividad funded this study.

Source: Marta Fallola Sánchez-Herrera – University of Extremadura
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is credited to UEx.
Original Research: Open access research for “STIM1 deficiency is linked to Alzheimer’s disease and triggers cell death in SH-SY5Y cells by upregulation of L-type voltage-operated Ca2+ entry” by Carlos Pascual-Caro, Maria Berrocal, Aida M. Lopez-Guerrero, Alberto Alvarez-Barrientos, Eulalia Pozo-Guisado, Carlos Gutierrez-Merino, Ana M. Mata, and Francisco Javier Martin-Romero in Journal of Molecular Medicine. Published August 7 2018.
doi:10.1007/s00109-018-1677-y

Cite This NeuroscienceNews.com Article
University of Extremadura”New Alzheimer’s Biomaker Identified with Help of CRISPR.” NeuroscienceNews. NeuroscienceNews, 9 October 2018.
<http://neurosciencenews.com/alzheimers-crispr-biomarker-9989/>.
University of Extremadura(2018, October 9). New Alzheimer’s Biomaker Identified with Help of CRISPR. NeuroscienceNews. Retrieved October 9, 2018 from http://neurosciencenews.com/alzheimers-crispr-biomarker-9989/
University of Extremadura”New Alzheimer’s Biomaker Identified with Help of CRISPR.” http://neurosciencenews.com/alzheimers-crispr-biomarker-9989/ (accessed October 9, 2018).

Abstract

STIM1 deficiency is linked to Alzheimer’s disease and triggers cell death in SH-SY5Y cells by upregulation of L-type voltage-operated Ca2+ entry

STIM1 is an endoplasmic reticulum protein with a role in Ca2+ mobilization and signaling. As a sensor of intraluminal Ca2+ levels, STIM1 modulates plasma membrane Ca2+ channels to regulate Ca2+ entry. In neuroblastoma SH-SY5Y cells and in familial Alzheimer’s disease patient skin fibroblasts, STIM1 is cleaved at the transmembrane domain by the presenilin-1-associated γ-secretase, leading to dysregulation of Ca2+ homeostasis. In this report, we investigated expression levels of STIM1 in brain tissues (medium frontal gyrus) of pathologically confirmed Alzheimer’s disease patients, and observed that STIM1 protein expression level decreased with the progression of neurodegeneration. To study the role of STIM1 in neurodegeneration, a strategy was designed to knock-out the expression of STIM1 gene in the SH-SY5Y neuroblastoma cell line by CRISPR/Cas9-mediated genome editing, as an in vitro model to examine the phenotype of STIM1-deficient neuronal cells. It was proved that, while STIM1 is not required for the differentiation of SH-SY5Y cells, it is absolutely essential for cell survival in differentiating cells. Differentiated STIM1-KO cells showed a significant decrease of mitochondrial respiratory chain complex I activity, mitochondrial inner membrane depolarization, reduced mitochondrial free Ca2+ concentration, and higher levels of senescence as compared with wild-type cells. In parallel, STIM1-KO cells showed a potentiated Ca2+ entry in response to depolarization, which was sensitive to nifedipine, pointing to L-type voltage-operated Ca2+ channels as mediators of the upregulated Ca2+ entry. The stable knocking-down of CACNA1C transcripts restored mitochondrial function, increased mitochondrial Ca2+ levels, and dropped senescence to basal levels, demonstrating the essential role of the upregulation of voltage-operated Ca2+ entry through Cav1.2 channels in STIM1-deficient SH-SY5Y cell death.

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.
No more articles